Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yeshwant D. Sanzgiri"'
Autor:
Andrew J. Souers, Nathaniel D. Catron, Geoff G.Z. Zhang, Xilu Wang, Ahmed A. Suleiman, Deanne Stolarik, Yi Shi, Ahmad Y. Sheikh, Yeshwant D. Sanzgiri, Saul H. Rosenberg, Yu-Ming Pu, Darren C. Phillips, Chang H. Park, Rajeev M. Menon, Kennan C. Marsh, Richard A. Marks, Joel D. Leverson, Yi-Yin Ku, Russell C. Klix, John C. Kalvass, Russell A. Judge, Jianguo Ji, Gary J. Jenkins, Richard Hong, Kaid C. Harper, Keith M. Fournier, Steven W. Elmore, Rohinton Edalji, Shuang Chen, Jie Chen, Orlando F. Bueno, Zhi-Fu Tao, Ahmed Hamed Salem
Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f852ee29a9488942fba6fce73ac0eaf
https://doi.org/10.1158/1535-7163.c.6543327.v1
https://doi.org/10.1158/1535-7163.c.6543327.v1
Autor:
Andrew J. Souers, Nathaniel D. Catron, Geoff G.Z. Zhang, Xilu Wang, Ahmed A. Suleiman, Deanne Stolarik, Yi Shi, Ahmad Y. Sheikh, Yeshwant D. Sanzgiri, Saul H. Rosenberg, Yu-Ming Pu, Darren C. Phillips, Chang H. Park, Rajeev M. Menon, Kennan C. Marsh, Richard A. Marks, Joel D. Leverson, Yi-Yin Ku, Russell C. Klix, John C. Kalvass, Russell A. Judge, Jianguo Ji, Gary J. Jenkins, Richard Hong, Kaid C. Harper, Keith M. Fournier, Steven W. Elmore, Rohinton Edalji, Shuang Chen, Jie Chen, Orlando F. Bueno, Zhi-Fu Tao, Ahmed Hamed Salem
1. Measured pKa values of ABBV-167 (Table S1. Ionization constants of ABBV-167) 2. Preparation of ABBV-167 on large scale (Scheme S1: Synopsis of GMP synthesis of ABBV-167) 3. Preparation of clinical ABBV-167 drug supply 4. Animal pharmacokinetics (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b82ad084c554229baf59a8bada6e495
https://doi.org/10.1158/1535-7163.22522290
https://doi.org/10.1158/1535-7163.22522290
Autor:
Darren C. Phillips, Gary J. Jenkins, Richard S. Hong, Chang H. Park, Richard A. Marks, Rohinton P. Edalji, Russell A. Judge, Geoff G. Z. Zhang, Nathaniel D. Catron, Jie Chen, Ahmed Salem, Ahmad Y. Sheikh, John C. Kalvass, Kaid C. Harper, Rajeev M. Menon, Kennan C. Marsh, Yeshwant D. Sanzgiri, Saul H. Rosenberg, Ahmed A. Suleiman, Yu-Ming Pu, Yi Shi, Keith M. Fournier, Zhi-Fu Tao, DeAnne Stolarik, Shuang Chen, Orlando F. Bueno, Xilu Wang, Jianguo Ji, Yi-Yin Ku, Andrew J. Souers, Joel D. Leverson, Russell C. Klix, Steven W. Elmore
Publikováno v:
Molecular cancer therapeutics. 20(6)
Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ca7b4ca005bb0064352f56f806f877
https://pubmed.ncbi.nlm.nih.gov/33785651
https://pubmed.ncbi.nlm.nih.gov/33785651
Autor:
Mignon L. Loh, Thalia A. Farazi, Daniel A. Morgenstern, C. Michel Zwaan, Kelly C. Goldsmith, Jean-Pierre Bourquin, Maria Verdugo, Yeshwant D. Sanzgiri, Josef Vormoor, David Hoffman, Mohamad Shebley, Betty Prine, Megan McNamee, Andrew E. Place, Jeremy A. Ross, Lia Gore, Ying Zhou, Su Young Kim, L. Leanne Lash-Fleming
Publikováno v:
Future Oncology, 14(21), 2115-2129. Future Medicine Ltd.
Venetoclax is a highly selective, potent BCL-2 inhibitor that is approved for some patients previously treated for chronic lymphocytic leukemia, and has shown promising activity in adult studies across several hematologic malignancies. Preclinical st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a538122e971b50ec243560df0e12db7a
https://doi.org/10.2217/fon-2018-0121
https://doi.org/10.2217/fon-2018-0121
Publikováno v:
AAPS PharmSciTech. 4:461-468
The objectives of this study were to investigate the effects of manufacturing parameters on the moisture sorption isotherms of some tablet formulations and to predict the moisture isotherms of the final formulations using polynomial equations. Three
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67ed08968b6108d2c6c08d1303d5de18
https://doi.org/10.1208/pt040459
https://doi.org/10.1208/pt040459
Publikováno v:
International Journal of Pharmaceutics. 125:55-61
The effect of SBE4-β-CD, a sulfobutyl ether derivative of β-cyclodextrin on the solubility and aqueous hydrolysis of the antitumor drug O6-benzylguanine (BG) was studied. SBE4-β-CD is an apparently parenterally safe anionic β-cyclodextrin derivat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8643300fe75b7389fb923579bfedd051
https://doi.org/10.1016/0378-5173(95)00112-v
https://doi.org/10.1016/0378-5173(95)00112-v
Autor:
Valentino J. Stella, Hyeyoun K. Lee, Yeshwant D. Sanzgiri, Elizabeth M. Topp, Luca Benedetti, Lisbeth R. Hume
Publikováno v:
International Journal of Pharmaceutics. 111:295-298
Hyaluronic acid benzyl ester films were studied for ocular delivery of prednisolone. The four polymers used were HYAFF 11 p25 (25% benzyl ester, 75% sodium salt), HYAFF 11 p50 (50% benzyl ester, 50% sodium salt), HYAFF 11 p75 (75% benzyl ester, 25% s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e359f9cf16a73333c785dacc603965c
https://doi.org/10.1016/0378-5173(94)90352-2
https://doi.org/10.1016/0378-5173(94)90352-2
Publikováno v:
International Journal of Pharmaceutics. 107:91-97
Mucoadhesive properties of hyaluronic acid (HA) benzyl esters were evaluated. The vertical tensile force of detachment of polymer films from porcine gastric mucosal surface was measured with a microdisplacement transducer. The HA esters, namely, HYAF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b4502770e9da03236440da7852de694
https://doi.org/10.1016/0378-5173(94)90446-4
https://doi.org/10.1016/0378-5173(94)90446-4
Publikováno v:
Polymers for Advanced Technologies. 3:317-321
Delivery of drugs to brain tumors is difficult due to the impermeability, and variable nature of the blood/tumor barrier. Of the various strategies designed to improve drug uptake-intracellularly and into the brain, cationic carriers seem to offer an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6462fe3d6423f21dc85ca377e2ca1770
https://doi.org/10.1002/pat.1992.220030606
https://doi.org/10.1002/pat.1992.220030606
Publikováno v:
Pharmaceutical Research. :418-421
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f35f50ee2ae69f71060d13ee7c2a541d
https://doi.org/10.1023/a:1015887910184
https://doi.org/10.1023/a:1015887910184